NBE-Therapeutics engages in the development of “next-generation” antibody drug conjugates (ADCs) leveraging its proprietary technology platforms for therapeutic antibody and site-specific conjugation technologies. NBE-Therapeutics has the goal to develop best-in-class ADC product candidates until clinical proof-of-concept in patients.
NBE-Therapeutics total Funding
NBE-Therapeutics latest funding size
Time since last funding
|3 years ago|
|Boehringer Ingelheim Venture Fund, PPF Group|
When was NBE-Therapeutics founded?
NBE-Therapeutics was founded in 2012.
Who are NBE-Therapeutics key executives?
NBE-Therapeutics's key executives are Ulf Grawunder, Jim O'Leary and Wouter Verhoeven.
Who are NBE-Therapeutics competitors?
Competitors of NBE-Therapeutics include Araris Biotech, LGC Biosearch Technologies and Fate Therapeutics.
Where is NBE-Therapeutics headquarters?
NBE-Therapeutics headquarters is located at Hochbergerstrasse 60C, Basel.
Where are NBE-Therapeutics offices?
NBE-Therapeutics has an office in Basel.
How many offices does NBE-Therapeutics have?
NBE-Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies